Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact

@article{Tefferi2014Type1V,
  title={Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact},
  author={Ayalew Tefferi and Terra L. Lasho and Christy M. Finke and Alem A. Belachew and Emnet A Wassie and Rhett P. Ketterling and Curtis A. Hanson and Animesh Pardanani},
  journal={Leukemia},
  year={2014},
  volume={28},
  pages={1568-1570}
}
317–329. 16 Suzuki T, Shen H, Akagi K, Morse HC, Malley JD, Naiman DQ et al. New genes involved in cancer identified by retroviral tagging. Nat Genet 2002; 32: 166–174. 17 Gulbagci NT, Li L, Ling B, Gopinadhan S, Walsh M, Rossner M et al. SHARP1/DEC2 inhibits adipogenic differentiation by regulating the activity of C/EBP. EMBO Rep 2009; 10: 79–86. 18 Matsunaga N, Inoue M, Kusunose N, Kakimoto K, Hamamura K, Hanada Y et al. Time-dependent interaction between differentiated embryo chondrocyte-2… CONTINUE READING